期刊文献+

^68Ga—DOTA—cNGR的制备及对荷肺腺癌裸鼠的显像研究 被引量:2

Preparation of ^68Ga-DOTA-cNGR and its application in imaging of the nude mice bearing human lung cancer
原文传递
导出
摘要 目的制备^68Ga-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸-环状NGR(DOTA-cNGR),并评价其在正常小鼠体内的生物分布及对荷肺腺癌裸鼠的靶向显像能力。方法以羟乙基哌嗪乙硫磺酸(HEPES)为缓冲体系(pH值5.0),水浴合成^68Ga—DOTA—cNGR,HPLC测定标记率及放化纯,观察其在人血清中的稳定性。进行^68Ga—DOTA—cNGR的正常小鼠体内生物分布和荷肺腺癌裸鼠活体microPET显像,对荷肺腺癌裸鼠的瘤组织进行病理及氨肽酶N(APN)的免疫组织化学分析。采用两样本t检验分析数据。结果^68Ga—DOTA—cNGR标记率为(99.8±0.1)%,性状稳定,在人血清中37℃保温2h后放化纯仍〉95%。正常小鼠体内生物分布结果表明,^68Ga—DOTA-cNGR主要经肾排泄,血液清除迅速,肝、胃肠道摄取较少;1h肾、血液、肝、胃、肠的放射性摄取分别为(1.61±0.22)、(0.19±0.07)、(0.25±0.24)、(0.16±0.04)、(0.12±0.05)%ID/g。荷肺腺癌裸鼠microPET显像可见肿瘤部位有放射性浓聚影,1h肿瘤与对侧正常肌肉T/NT高达7.61±0.47,经DOTA—cNGR特异性阻断后降至1.83±0.25,阻断前后差异有统计学意义(t=18.80,P〈0.05)。免疫组织化学检查证实APN特异性聚集于肿瘤新生血管表面。结论^68Ga-DOTA—cNGR易于制备,标记率和放化纯高,在人血清中的稳定性好,具有良好的代谢及肺腺瘤靶向特性,有望用于肺癌显像。 Objective To prepare ^68 Ga- 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetroaceticacid- cyclo NGD (DOTA-cNGR) and evaluate its biodistribution in normal mice and imaging efficacy in nude mice bearing human lung cancer. Methods ^68Ga-DOTA-cNGR was synthesized through water bath at pH= 5.0 with hydroxyl ethyl piperazine ethane sulfonic acid (HEPES) as the buffer system. The radiolabeling yield and radiochemistry purity were analyzed with HPLC. The stability of ^68Ga-DOTA-eNGR in serum was measured. The biodistribution of ^68g Ga-DOTA-cNGR was studied in the normal mice (expressed as %ID/g of tissues) and the nude mice bearing human lung cancer xenografts were imaged in vivo by microPET. Pathological and immunohistochemical analyses were performed on tumor tissues. Two-sample t test was used to analyze the data. Results The radiolabeling yield was (99.8±0.1)% and radiochemical purity after 2 h in serum was more than 95%. Biodistribution study showed rapid clearance of ^68Ga-DOTA-eNGR from the blood, and excretion was mainly via kidney with little uptake in the liver and gastrointestinal tract. The tracer uptake in kidneys, blood, liver, stomach, and intestine was ( 1.61 ± 0.22 ) , ( 0.19± 0.07 ) , ( 0.25 ± 0. 24), (0.16±0.04), (0.12±0.05) %ID/g respectively at 1 h post injection. The tumor uptake was significantly elevated on microPET with maximum T/NT of 7.61±0.47 at 1 h post injection. After specific blockage by DOTA-cNGR, the T/NT was significantly reduced to 1.83:1:0.25 (t= 18.80, P〈0.05). The expression of aminopeptidase N was detected by immunohistochemistry. Conclusion ^68 Ga-DOTA-eNGR could be successfully prepared with high radiolabeling yield and radioehemical purity. Its good stability in serum, ideal biodistribution and imaging characteristics are factors favoring the potential for imaging human lung cancer with over-expression of NGR receptors.
出处 《中华核医学与分子影像杂志》 CSCD 北大核心 2014年第3期222-225,共4页 Chinese Journal of Nuclear Medicine and Molecular Imaging
基金 国家自然科学基金(81171383,81271604)
关键词 天冬酰胺-甘氨酸-精氨酸 镓放射性同位素 肺肿瘤 放射性核素显像 小鼠 Asparagine-glycine-arginine imaging Mice, nude Gallium radioisotopes Lung neoplasms Radionuclide
  • 相关文献

参考文献18

  • 1韩安勤,胡旭东,邢力刚.肿瘤血管生成的PET检测[J].中华核医学与分子影像杂志,2012,32(6):478-480. 被引量:3
  • 2Zhang K, Chen W, Zhang Y, et al. An anti-human CD13 mono- clonal antibody that suppresses the suppressive function of Treg cells [ J ]. Monoclon Antib Immunodiagn Immunother, 2013, 32 : 16-20.
  • 3Luan Y, Xu W. The structure and main functions of aminopeptid- ase N[J]. Curr Med Chem, 2007, 14: 639-647.
  • 4Ito S, Miyahara R, Takahashi R, et al. Stromal aminopeptidase N expression: correlation with angiogenesis in non-small-cell lung cancer[J]. Gen Thorac Cardiovasc Surg, 2009, 57: 591-598.
  • 5Dreischaltick J, Schwtippe C, Spieker T, et al. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile [ J ]. Int J Oncol, 2010, 37: 1389-1397.
  • 6Luo LM, Huang Y, Zhao BX, et al. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclita- xel[J]. Biomaterials, 2013, 34: 1102-1114.
  • 7Zucali PA, Simonelli M, De Vincenzo F, et al. Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours[ J]. Br J Cancer, 2013, 108: 58-63.
  • 8Meng J, Yan Z, Wu Y, et al. Preclinical safety evaluation of IFN alpha2a-NGR[J]. Regul Toxicol Pharmacol, 2008, 50: 294-302.
  • 9Santoro A, Pressiani T, Citterio G, et al. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma [ J 1. Br J Cancer, 2010, 103: 837-844.
  • 10马温惠,汪静,杨卫东,王喆,李桂玉.^131I-NGR的制备及人CD13表达细胞株的体外筛选[J].中华核医学与分子影像杂志,2012,32(6):447-451. 被引量:2

二级参考文献69

  • 1孙俊杰,范我,许玉杰,张友九,朱然,胡明江.^(125)I-[Tyr^3]-octreotide内化及杀伤NCI-H446细胞的研究[J].中华核医学杂志,2004,24(3):144-146. 被引量:9
  • 2孟洁如,颜真,赵宁,张英起.导向性人干扰素α2a工程菌的高密度发酵[J].第四军医大学学报,2004,25(23):2144-2147. 被引量:10
  • 3王喆,汪静,贾林涛,李国权,程时武,王喜青,杨安钢.hsstr2基因转染肿瘤细胞的受体显像研究[J].中华核医学杂志,2005,25(5):275-278. 被引量:3
  • 4Bertilaccio MT, Grioni M, Sutherland BW, et al. Vasculaature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin a gainst prostate cancer[J]. Prostate, 2008, 68: 1 105-1 115.
  • 5Fukasawa K, Fujii K, Saitoh Y, et al. Aminopep- tidase N (APN/CD13) is selectively expressed in vascularendothelial cells and play a multiple roles in angiogenesis[J]. Cancer Letters, 2006, 243: 135-143.
  • 6Schmidt PF, Suzanne L,^188Re DD-3B6/22 Fab9 for use in therapy of ovarian cancer: labelling and animal studies[J]. Nuclear Medicine & Biology, 1998, 25: 639-649.
  • 7Schechter NR, Yang DJ, Azhdarinia A, et al. As- sessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal anti- body[J]. Anticancer Drugs, 2003, 14: 49-56.
  • 8Yang DJ, Azhdarinia Ali, Edmund Ki. Tumor specific imaging using Tc-99m and Ga-68 labeled radiopharmaeeuticals [J].Current Medical Ima- ging Reviews, 2005, 1: 25-34.
  • 9Klein SA, Hemann S, Dietrich JW, et al. Trans- plantation related toxicity and acute intestinal graft-versus-host disease after conditioning regi- mens intensified with Rhenium-188 labeled anti- CD66 monoclonal anti-bodies[J]. Blood, 2002, 99 (6) : 2 270.
  • 10Bergers G, Benjamin LE. Angiogenesis; tumoeri- genesis and the angiogenic switch[J].Nat Rev Cancer, 2003, 3: 401-410.

共引文献6

同被引文献10

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部